Kikuchi Y, Oomori K, Kizawa I, Hirata J, Kita T, Miyauchi M, Kato K
Department of Obstetrics and Gynecology, National Defense Medical College, Saitama, Japan.
Cancer Res. 1987 Dec 15;47(24 Pt 1):6459-61.
The present study was designed to potentiate the antineoplastic effects of cisplatin by combination with calmodulin antagonists [N-(6-amino-hexyl)-5-chloro-1-naphthalenesulfonamide (W-7) and N-(6-aminohexyl)-1-naphthalenesulfonamide (W-5)] in nude mice bearing human ovarian carcinoma. Tumor growth of nude mice treated with W-7 or W-5 combined with cisplatin was significantly inhibited, compared to that of nude mice treated with W-7 alone, W-5 alone, or cisplatin alone. Although treatment with cisplatin alone markedly inhibited lytic activity of spleen cells from tumor-bearing nude mice against the tumor cells, the inhibitory effect was eliminated by combination with W-7 or W-5. There was no significant difference in survival time among untreated, cisplatin-treated, W-7-treated, and W-5-treated groups. Only when cisplatin was followed by W-7 or W-5 was a significant enhancement by W-7 or W-5 of the antitumor effect of cisplatin observed with respect to inhibition of tumor growth as well as prolongation of survival time.
本研究旨在通过将顺铂与钙调蛋白拮抗剂[N-(6-氨基己基)-5-氯-1-萘磺酰胺（W-7）和N-(6-氨基己基)-1-萘磺酰胺（W-5）]联合使用，增强顺铂对荷人卵巢癌裸鼠的抗肿瘤作用。与单独使用W-7、单独使用W-5或单独使用顺铂的裸鼠相比，用W-7或W-5联合顺铂治疗的裸鼠肿瘤生长受到显著抑制。虽然单独使用顺铂治疗可显著抑制荷瘤裸鼠脾细胞对肿瘤细胞的裂解活性，但与W-7或W-5联合使用后，这种抑制作用被消除。未治疗组、顺铂治疗组、W-7治疗组和W-5治疗组的生存时间没有显著差异。只有当顺铂之后使用W-7或W-5时，才观察到W-7或W-5在抑制肿瘤生长以及延长生存时间方面对顺铂抗肿瘤作用有显著增强。
